Coronavirus - COVID 19 HAS veille

Vaccins COVID-19 : l’ANSM met en place un comité d’experts hebdomadaire sur les effets thrombotiques

Data on the clinical outcomes of children with COVID-19 are scarce, particularly in
those with asymptomatic and mild disease.1,2 Studies involving adults suggest that
long-term multisystem sequelae and complications can occur, even with mild COVID-19.3
We aimed to describe medium-term clinical outcomes 3–6 months after diagnosis in children
with COVID-19 presenting to a tertiary paediatric hospital.

Site ORS

Interim guidance on the benefits of full vaccination against COVID-19 for transmission and implications for non-pharmaceutical interventions.

This document aims to provide interim guidance on the risks for fully vaccinated individuals to develop or transmit
infection that will give rise to severe COVID-19 disease in the context of the current epidemiological and vaccine
coverage situation in the EU/EEA.

The prior year has seen an unprecedented number of vaccine candidates directed at the COVID-19 pandemic. This report examines these vaccines and the related research effort, both traditional and forward-looking, to illustrate the advantages and disadvantages of their technologies, to denote the use of adjuvants and delivery systems in their application, and to provide a perspective on their future direction.

COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low platelets

[:fr]  En s’appuyant sur des études épidémiologiques de terrain et sur la cohorte hospitalière FrenchCOVID coordonnée par l’Inserm, des équipes de l’Institut Pasteur, du CNRS et

As the first clinical trials in young children start, here's what scientists want to know.

FDA announces streamlined EUA amendment for certain molecular test developers to pool specimens as part of a serial testing program.

CRISPR-based nucleic-acid detection is an emerging technology for molecular diagnostics. However, these methods generally require several hours and could cause amplification errors, due to the pre-amplification of target nucleic acids to enhance the detection sensitivity. Here, we developed a platform that allows “CRISPR-based amplification-free digital RNA detection (SATORI)”, by combining CRISPR-Cas13-based RNA detection and microchamber-array technologies. SATORI detected single-stranded RNA targets with maximal sensitivity of ~10 fM in <5 min, with high specificity. Furthermore, the simultaneous use of multiple different guide RNAs enhanced the sensitivity, thereby enabling the detection of the SARS-CoV-2 N-gene RNA at ~5 fM levels. Therefore, we hope SATORI will serve as a powerful class of accurate and rapid diagnostics. The authors develop a platform (SATORI) that enables accurate and rapid detection of single-stranded RNA at a single-molecule level without a pre-amplification step. As a proof-of-concept, they demonstrate its utility in detecting the SARS-CoV-2 N gene at a minimum concentration of ~5 fM, which is much lower than other amplification-free CRISPR-Cas-based methods.

Campaigns to battle tuberculosis, measles and polio have all been set back.